It comes after the first round of negotiations between the US and Iran in Pakistan last weekend ended without a deal.
After receiving a drug rejection from the FDA, Woburn-based Replimune Group (Nasdaq: REPL) has informed the state that it ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results